GeronFRA:GON +1.00%37 Days Inventory is 6,697.28 as of Mar. 2026, which is 22% below its 10-year median of 8,612.75. GuruFocus rates FRA:GON with a GF Score™ of 37/100 and a GF Value™ of €6.15 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 637 Biotechnology companies, Geron ranks worse than 98.27% on this metric.
Days Inventory is also known as Days Sales of Inventory (DSI). Geron's Average Total Inventories for the
three
months ended in Mar. 2026 was €107.5 Mil. Geron's Cost of Goods Sold for the
three
months ended in Mar. 2026 was €1.5 Mil.
Hence, Geron's Days Inventory for the
three
months ended in Mar. 2026 was 6,697.28.
The historical rank and industry rank for Geron's Days Inventory or its related term are showing as below:
FRA:GON'
s Days Inventory Range Over the Past 10 Years
Min: 5975 Med: 8612.75 Max: 11250.49
Current: 6568.63
During the past 13 years, Geron's highest Days Inventory was 11250.49. The lowest was 5975.00. And the median was 8612.75.
FRA:GON's Days Inventory is ranked worse than 98.27% of 637
companies
in the Biotechnology industry
Industry Median: 183.23
vs FRA:GON: 6568.63
Geron's Days Inventory
increased
from Mar. 2025 (3,637.61) to Mar. 2026 (6,697.28).
It might indicate that Geron's sales slowed down.
Warning Sign:
If a company builds up inventory, it may mean it is having difficulties selling its goods.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Geron's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.01.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Geron's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 2.40.
Geron (FRA:GON) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Geron's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Geron's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Geron Days Inventory Related Terms
Geron Days Inventory Historical Data
* Premium members only.
The historical data trend for Geron's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:GON vs SPRY, PHAT, DSGN: Days Inventory Comparison
For the Biotechnology subindustry, Geron's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Geron Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Geron's Days Inventory distribution charts can be found below:
* The bar in red indicates where Geron's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Geron (FRA:GON) has a Days Inventory of 6,697.28 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Geron and its competitors. This is 22% below median its historical median of 8,612.75. Over the past decade, Geron's Days Inventory has ranged from 5,975.00 to 11,250.49. According to the industry distribution chart, Geron ranks #626 out of 637 companies in the Biotechnology industry, placing it in the top 98.3%.
Is Geron's Days Inventory too high?
Geron's current Days Inventory of 6,697.28 is 22% below median its 10-year median of 8,612.75. Over the past 10 years, this metric has ranged from a low of 5,975.00 to a high of 11,250.49. The Biotechnology industry median Days Inventory is 183.23. Geron's value of 6,697.28 is 3555.1% above this industry median. Based on the distribution chart, Geron ranks #626 out of 637 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Geron has a GF Score™ of 37/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Geron's Days Inventory compare to SPRY and PHAT?
According to the Biotechnology industry distribution chart, Geron ranks #626 out of 637 companies for Days Inventory. This places Geron in the lower half of its industry. The industry median Days Inventory is 183.23. Geron's value of 6,697.28 is 3555.1% above this benchmark. Historically, Geron's own Days Inventory has ranged from 5,975.00 to 11,250.49 over the past decade. While the company's 10-year median is 8,612.75 vs. the industry median of 183.23, Geron has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 183.23, based on 637 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Geron's current Days Inventory of 6,697.28 is 3555.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Geron and its competitors. For the Biotechnology industry, the median Days Inventory is 183.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Geron's current Days Inventory is 6,697.28, which is 22% below median its own 10-year median of 8,612.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Geron stock overvalued right now?
Based on GuruFocus' analysis, Geron (FRA:GON) is currently considered Possible Value Trap. The stock's GF Value™ is €6.15, compared to a current price of €1.36 — trading 77.9% below its estimated fair value. The current Days Inventory is 6,697.28, which is 22% below median its 10-year median of 8,612.75 and 3555.1% above the Biotechnology industry median of 183.23. Geron's overall GF Score™ is 37/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Geron (FRA:GON), the current Days Inventory is 6,697.28 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Geron (FRA:GON) Overvalued in 2026?
Based on GuruFocus' analysis, Geron stock appears to be undervalued.
The current stock price of €1.36 is trading 77.9% below its estimated GF Value™ of €6.15.
GuruFocus considers Geron to be Possible Value Trap.
Key valuation signals for FRA:GON:
Days Inventory: 6,697.28 (22% below median its 10-year median of 8,612.75)
GF Value™: €6.15 vs. price of €1.36 (77.9% below fair value)
Industry Position: 3555.1% above the Biotechnology median (#626 of 637)
No single metric tells the full story. See the FRA:GON stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
37GF Score
Get the complete analysis for FRA:GON
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:GON has been successfully added to your 
